Ourofino (BSP:OFSA3) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:OFSA3 Ourofino SA BSP:OFSA3
82 GF Score
Price R$24.52
GF Value R$28.13
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Ourofino Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

BSP:OFSA3
82GF Score
Ourofino SA BSP:OFSA3
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ourofino (BSP:OFSA3) Overvalued in 2026?

Based on GuruFocus' analysis, Ourofino stock appears to be undervalued. The current stock price of R$24.52 is trading 12.8% below its estimated GF Value™ of R$28.13. GuruFocus considers Ourofino to be Modestly Undervalued.

Key valuation signals for BSP:OFSA3:

  • Future Policy Benefits:
  • GF Value™: R$28.13 vs. price of R$24.52 (12.8% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ourofino Business Description

Address Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
82GF Score

Get the complete analysis for BSP:OFSA3

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$24.52
Price
R$28.13
GF Value